POSTPONED: Extended INSIGHT: Natural or synthetic? Magic mushroom products for psychedelic therapies

This conversation will explore the discovery and development of naturally-derived psychedelics. Although the majority of psychedelic compounds that are currently under investigation originate in the natural world, natural psychedelics make up a proportionally smaller percentage of current drug candidates than their synthetically-created counterparts.
Benjamin Lightburn, CEO and Co-Founder of Filament Health, Dr. Joshua Woolley, Director of UCSF’s Translational Psychedelic Research Program, and Dr. Henrik Jungaberle will explore the differences between natural and synthetic psychedelics, shedding light on a less well-understood area of the field, and the potential benefits of natural psychedelics compared with synthetics.
Lightburn and Filament Health are entering the first botanical psychedelic drug candidates, magic mushroom extracts, into FDA clinical trials which will be led by Dr. Woolley at UCSF.

We’ll delve into botanical extraction processes, clinical trial design, regulatory considerations, and of course, magic mushroom extracts themselves.